Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-12-29 00:00:00 ET · period of report 2023-12-27 · accession 0001883850-23-000108 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-12-29 | 2023-12-27+ | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $378.98 | +1,600 | 22.4K | +8% | +$606.4K |
| DM | 2023-12-29 | 2023-12-27+ | REGN | Landry Robert E | EVP Fin CFO | F - Tax | $878.93 | -1,154 | 21.8K | -5% | -$1.01M |
| DM | 2023-12-29 | 2023-12-27+ | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $0.00 | -1,600 | 17.7K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-27 | M | A | 750 | $378.98 | 22,111 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-27 | F | D | 542 | $872.21 | 21,569 | D | — | — | |
| 3 | Common | Common Stock | 2023-12-28 | M | A | 850 | $378.98 | 22,419 | D | — | — | |
| 4 | Common | Common Stock | 2023-12-28 | F | D | 612 | $884.88 | 21,807 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-12-27 | M | D | 750 | $0.00 | 18,587 | D | $378.98 · — to 2027-12-12 | 750 Common Stock | (F1) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
| 6 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-12-28 | M | D | 850 | $0.00 | 17,737 | D | $378.98 · — to 2027-12-12 | 850 Common Stock | (F1) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |